'''Endometrial Intraepithelial Neoplasia, (EIN)''' is a premalignant lesion of the uterine lining that predisposes to endometrioid endometrial adenocarcinoma.  It is composed of a collection of abnormal [[endometrial]] cells, arising from the glands that line the [[uterus]], which have a tendency, over time to progress to the most common form of uterine [[cancer]] —  endometrial [[adenocarcinoma]], endometrioid type.

==History==
EIN lesions have been discovered by a combination of molecular, histologic, and clinical outcome studies beginning in the 1990s which provide a multifaceted characterization of this disease.  They are a subset of a larger mixed group of lesions previously called "endometrial [[hyperplasia]]<ref name=A>{{cite book |author=Mutter GL, Duska L, Crum CP |chapter=Endometrial Intraepithelial Neoplasia |editor=Crum CP, Lee K |title=Diagnostic Gynecologic and Obstetric Pathology |publisher=Saunders |location=Philadelphia PA |year=2005 |pages=493–518 }}</ref><ref name=B>{{cite book |author=Silverberg SG, Mutter GL, Kurman RJ, Kubik-Huch RA, Nogales F, Tavassoli FA |chapter=Tumors of the uterine corpus: epithelial tumors and related lesions |editor=Tavassoli FA, Stratton MR |title=WHO Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs |publisher=IARC Press |location=Lyon, France |year=2003 |pages=221–232 }}</ref>" The EIN diagnostic schema is intended to replace the previous "[[endometrial hyperplasia]]" classification as defined by the [[World Health Organization]] in 1994, which have been separated into [[benign]] (benign endometrial hyperplasia) and [[premalignant]] (EIN) classes in accordance with their behavior and clinical management.<br>
EIN should not be confused with an unrelated entity, serous intraepithelial carcinoma ("serous EIC"), which is an early stage of a different [[tumor]] type known as papillary serous adenocarcinoma that also occurs in the same location within the uterus.

==Clinical Aspects ==
The average age at time of EIN diagnosis is approximately 52 years, compared to approximately 61 years for carcinoma.  The timeframe and likelihood of EIN progression to cancer, however, is not constant amongst all women.  Some cases of EIN are first detected as residual premalignant disease in women who already have carcinoma, whereas other EIN lesions disappear entirely and never lead to cancer.  For this reason, treatment benefits and risks must be individualized for each patient under the guidance of an experienced physician. <br>
Risk factors for development of EIN and the endometrioid type of endometrial carcinoma include exposure to estrogens without opposing progestins, obesity, diabetes, and rare hereditary conditions such as [[hereditary nonpolyposis colorectal cancer]].  Protective factors include use of [[combined oral contraceptive pills]] (low dose estrogen and progestin), and prior use of a contraceptive [[intrauterine device]].

==Biology==
EIN lesions demonstrate all of the behaviors and characteristics of a premalignant, or precancerous, lesion.

'''Precancer Features of EIN (Table I)'''. The cells of an EIN lesion are genetically different than normal and malignant tissues, and have a distinctive appearance under the light microscope.  EIN cells are already [[neoplasm|neoplastic]], demonstrating a [[monoclonal growth pattern]] and clonally distributed mutations.  Progression of EIN to carcinoma, effectively a conversion from a benign neoplasm to a malignant neoplasm, is accomplished through acquisition of additional mutations and accompanied by a change in behavior characterized by the ability to invade local tissues and metastasize to regional and distant sites.

'''Table I''': Precancer Characteristics of  EIN
{| border="1"
! Precancer Characteristics !! EIN Evidence
|-
|Precancers differ from normal tissue || <li> Monoclonal EIN<ref name=C>{{cite journal |author=Mutter GL, Baak JP, Crum CP, Richart RM, Ferenczy A, Faquin WC |title=Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry |journal=J. Pathol. |volume=190 |issue=4 |pages=462–9 |year=2000 |month=March |pmid=10699996 |doi=10.1002/(SICI)1096-9896(200003)190:4<462::AID-PATH590>3.0.CO;2-D }}</ref><ref name=D>{{cite journal |author=Jovanovic AS, Boynton KA, Mutter GL |title=Uteri of women with endometrial carcinoma contain a histopathological spectrum of monoclonal putative precancers, some with microsatellite instability |journal=Cancer Res. |volume=56 |issue=8 |pages=1917–21 |year=1996 |month=April |pmid=8620514 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=8620514}}</ref><ref name=E>{{cite journal |author=Mutter GL, Chaponot ML, Fletcher JA |title=A polymerase chain reaction assay for non-random X chromosome inactivation identifies monoclonal endometrial cancers and precancers |journal=Am. J. Pathol. |volume=146 |issue=2 |pages=501–8 |year=1995 |month=February |pmid=7856759 |pmc=1869842 }}</ref><ref name=F>{{cite journal |author=Esteller M, García A, Martínez-Palones JM, Xercavins J, Reventós J |title=Detection of clonality and genetic alterations in endometrial pipelle biopsy and its surgical specimen counterpart |journal=Lab. Invest. |volume=76 |issue=1 |pages=109–16 |year=1997 |month=January |pmid=9010454 }}</ref>  arise from polyclonal normal field.<ref name=G>{{cite journal |author=Mutter GL, Boynton KA |title=X chromosome inactivation in the normal female genital tract: implications for identification of neoplasia |journal=Cancer Res. |volume=55 |issue=21 |pages=5080–4 |year=1995 |month=November |pmid=7585555 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=7585555}}</ref><li> Mutations are acquired in EIN.<ref name=F/><ref name=H>{{cite journal |author=Esteller M, Catasus L, Matias-Guiu X, ''et al.'' |title=hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis |journal=Am. J. Pathol. |volume=155 |issue=5 |pages=1767–72 |year=1999 |month=November |pmid=10550333 |pmc=1866976 |doi=10.1016/S0002-9440(10)65492-2 |url=http://linkinghub.elsevier.com/retrieve/pii/S0002-9440(10)65492-2}}</ref><ref name=I>{{cite journal |author=Pontzer CH, Bazer FW, Johnson HM |title=Antiproliferative activity of a pregnancy recognition hormone, ovine trophoblast protein-1 |journal=Cancer Res. |volume=51 |issue=19 |pages=5304–7 |year=1991 |month=October |pmid=1913653 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=1913653}}</ref><ref name=J>{{cite journal |author=Mutter GL, Wada H, Faquin WC, Enomoto T |title=K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis |journal=MP, Mol. Pathol. |volume=52 |issue=5 |pages=257–62 |year=1999 |month=October |pmid=10748874 |pmc=395707 |url=http://mp.bmj.com/cgi/pmidlookup?view=long&pmid=10748874 |doi=10.1136/mp.52.5.257}}</ref><ref name=K>{{cite journal |author=Maxwell GL, Risinger JI, Gumbs C, ''et al.'' |title=Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias |journal=Cancer Res. |volume=58 |issue=12 |pages=2500–3 |year=1998 |month=June |pmid=9635567 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=9635567}}</ref><ref name=L>{{cite journal |author=Sasaki H, Nishii H, Takahashi H, ''et al.'' |title=Mutation of the Ki-ras protooncogene in human endometrial hyperplasia and carcinoma |journal=Cancer Res. |volume=53 |issue=8 |pages=1906–10 |year=1993 |month=April |pmid=8467512 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=8467512}}</ref><ref name=M>{{cite journal |author=Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ, Ellenson LH |title=PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma |journal=Cancer Res. |volume=58 |issue=15 |pages=3254–8 |year=1998 |month=August |pmid=9699651 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=9699651}}</ref>
|-
|Precancers share some, but not all, features of cancer || <li> EIN-cancer lineage hierarchy<ref name=N>{{cite journal |author=Mutter GL, Boynton KA, Faquin WC, Ruiz RE, Jovanovic AS |title=Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer |journal=Cancer Res. |volume=56 |issue=19 |pages=4483–6 |year=1996 |month=October |pmid=8813144 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=8813144}}</ref> <li> EIN may share PTEN,<ref name=K/><ref name=M/><ref name=O>{{cite journal |author=Mutter GL, Lin MC, Fitzgerald JT, ''et al.'' |title=Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers |journal=J. Natl. Cancer Inst. |volume=92 |issue=11 |pages=924–30 |year=2000 |month=June |pmid=10841828 |url=http://jnci.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=10841828 |doi=10.1093/jnci/92.11.924}}</ref> K-ras,<ref name=I/><ref name=J/><ref name=L/><ref name=P>{{cite journal |author=Duggan BD, Felix JC, Muderspach LI, Tsao JL, Shibata DK |title=Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma |journal=Cancer Res. |volume=54 |issue=6 |pages=1604–7 |year=1994 |month=March |pmid=8137266 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=8137266}}</ref> MLH1<ref name=H/><ref name=Q>{{cite journal |author=Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG |title=MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas |journal=Oncogene |volume=17 |issue=18 |pages=2413–7 |year=1998 |month=November |pmid=9811473 |doi=10.1038/sj.onc.1202178 }}</ref> changes with cancer. <li> Both EIN and cancer are monoclonal.<ref name=C/><ref name=E/><ref name=F/><ref name=R>{{cite journal |author=Doherty T, Connell J, Stoerker J, Markham N, Shroyer AL, Shroyer KR |title=Analysis of clonality by polymerase chain reaction for phosphoglycerate kinase-1. Heteroduplex generator |journal=Diagn. Mol. Pathol. |volume=4 |issue=3 |pages=182–90 |year=1995 |month=September |pmid=7493137 |doi=10.1097/00019606-199509000-00005 }}</ref><ref name=S>{{cite journal |author=Shroyer KR, Gudlaugsson EG |title=Analysis of clonality in archival tissues by polymerase chain reaction amplification of PGK-1 |journal=Hum. Pathol. |volume=25 |issue=3 |pages=287–92 |year=1994 |month=March |pmid=8150459 |doi=10.1016/0046-8177(94)90201-1 }}</ref>
|-
|Precancers increase risk for carcinoma || <li> Elevated concurrent cancer rate (39% in first year after EIN diagnosis)<ref name=T>{{cite journal |author=Baak JP, Mutter GL, Robboy S, ''et al.'' |title=The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system |journal=Cancer |volume=103 |issue=11 |pages=2304–12 |year=2005 |month=June |pmid=15856484 |pmc=2600877 |doi=10.1002/cncr.21058 }}</ref> <li> EIN elevates future cancer risk 45-fold.<ref name=T/>
|-
|Precancers can be diagnosed || <li>Morphometric reference standard (D-Score) for EIN diagnosis.<ref name=C/><ref name=U>Mutter GL. Endometrial Precancer Type Collection [On Line]. http://www.endometrium.org 2000.</ref><ref name=V>{{cite journal |author=Mutter GL |title=Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group |journal=Gynecol. Oncol. |volume=76 |issue=3 |pages=287–90 |year=2000 |month=March |pmid=10684697 |doi=10.1006/gyno.1999.5580 |url=http://linkinghub.elsevier.com/retrieve/pii/S0090825899955804}}</ref><ref name=W>{{cite journal |author=Mutter GL |title=Histopathology of genetically defined endometrial precancers |journal=Int. J. Gynecol. Pathol. |volume=19 |issue=4 |pages=301–9 |year=2000 |month=October |pmid=11109157 |url=http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0277-1691&volume=19&issue=4&spage=301 |doi=10.1097/00004347-200010000-00002}}</ref> <li> Subjective EIN diagnosis using criteria (Table 2).<ref name=X>{{cite journal |author=Hecht JL, Ince TA, Baak JP, Baker HE, Ogden MW, Mutter GL |title=Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis |journal=Mod. Pathol. |volume=18 |issue=3 |pages=324–30 |year=2005 |month=March |pmid=15529181 |pmc=2573865 |doi=10.1038/modpathol.3800328 }}</ref>
|-
|Cancer must arise from cells within the precancer || <li> EIN-cancer lineage hierarchy.<ref name=N/> <li> EIN may share PTEN,<ref name=K/><ref name=M/><ref name=O/> K-ras,<ref name=I/><ref name=J/><ref name=L/><ref name=P/> MLH1<ref name=H/><ref name=Q/> changes with resultant cancer.
|}

'''EIN Biomarkers. (Figure 1)'''. There are no single biomarkers which are completely informative in recognition of EIN.  The tumour suppressor gene [[PTEN gene|PTEN]] is frequently inactivated in EIN, being abnormally turned off in approximately 2/3 of all EIN lesions.  This can be seen with special tissue stains applied to histological sections known as PTEN [[immunohistochemistry]], in which the brown PTEN protein is seen to be absent in the crowded tubular glands that make up an EIN lesion. 
<br>
[[Image:EIN PTEN 1024.jpg|thumb|500px|none|
'''Figure I'''. Tissue stain ([[immunohistochemistry]]) for the  [[PTEN gene|PTEN tumor suppressor gene]] showing loss of the PTEN protein in the round and tubular glands which are clustered tightly within an EIN lesion. Brown color indicates the PTEN protein is present.]]

==Diagnosis ==
Diagnosis of EIN lesions is of clinical importance because of the increased risk of coexisting (39% of women with EIN will be diagnosed with carcinoma within one year)  or future (the long term endometrial cancer risk is 45 times greater for a woman with EIN compared to one with only a benign endometrial histology) endometrial cancer.  Diagnostic terminology is that used by [[pathology|pathologists]], physicians who diagnose human disease by examination of histologic preparations of excised tissues.  Critical distinctions in EIN diagnosis are separation from benign conditions such as benign endometrial hyperplasia (a field effect in endometrial tissue caused by excessive stimulation by the hormone [[estrogen]]), and cancer. 
<br>
The spectrum of disease which must be distinguished from EIN '''(Table II)''' includes benign endometrial hyperplasia and carcinoma:<ref name=B/>

'''Table II:''' Disease classes that need to be distinguished from EIN.
{| border="1" style="text-align:center"
|-
! Disease<br> Class !! Endometrial<br> Topography !! Functional<br> Category !! Treatment
|-
|Benign<br> endometrial<br> hyperplasia || Diffuse || Hormone<br> (estrogen)<br> Effect || Hormonal therapy
|-
|EIN,<br> Endometrial<br> Intraepithelial<br> Neoplasia || Focal<br> progressing to<br> diffuse<br> (clonal) || Precancer || Hormonal or<br> surgical
|-
|Endometrial<br> Adenocarcinoma || Focal<br> progressing to<br> diffuse<br> (clonal) || Cancer || Surgical<br> stage-based
|}
<br>
EIN may be diagnosed by a trained pathologist by examination of tissue sections of the endometrium.  All of the following diagnostic criteria must be met in a single area of one tissue fragment to make the diagnosis '''(Table III)'''.  
<br>
<br>
'''Table III:''' EIN diagnosis.
{| border="1" 
|-
!
! EIN Criterion
!Comments
|-
|1 || Architecture || Gland area exceeds that of stroma, usually in a localized region.
|-
|2 || Cytological<br> Alterations || Cytology differs between architecturally crowded focus and background.
|-
|3 || Size greater than 1mm || Minimum linear dimension should exceed 1mm. Smaller lesions have unknown natural history.
|-
|4 || Exclude mimics || Basalis, normal secretory, polyps, repair, lower uterine segment, cystic atrophy, tangential sections, menstrual collapse, disruption artifact, etc.
|-
|5 || Exclude Cancer || Carcinoma should be diagnosed if: glands are mazelike and rambling, there are solid areas of epithelial growth, or there are significant bridges or cribriform areas. 
|}

==References==
{{reflist}}

==External links==
'''Patient Resources'''
* [http://www.cancer.org American Cancer Society]
* [http://www.wcn.org Women's Cancer Network] an educational and research organization
* [http://www.gog.org Gynecologic Oncology Group] an NIH-Funded research group that runs clinical trials
* [http://oncolink.upenn.edu OncoLink] an excellent educational site from the U. of Pennsylvania
* Find a board certified specialist at the [http://www.sgo.org Society of Gynecologic Oncologists]
<br>
<br>
'''Pathology'''
* [http://www.uscap.org US and Canadian Academy of Pathology]
* [http://www.endometrium.org www.endometrium.org] a pathology site focusing on endometrial disease
<br>
<br>
 '''PTEN Gene'''
* [http://www.cancerindex.org/geneweb/PTEN.htm Cancer Genetics Web] PTEN entry
* [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&db=PubMed&term=PTEN+endometr* PTEN and the Endometrium at PubMed]
* [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene&cmd=Retrieve&dopt=full_report&list_uids=5728 Entrez Gene] PTEN entry
<br>
<br>
 '''Other'''
* [http://www.cancer.gov/cancer_information/ CancerNet] an NIH database with clinical and scientific information
* [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed PubMed] a search engine and database for Medical Literature

{{Genital neoplasia}}

{{DEFAULTSORT:Endometrial Intraepithelial Neoplasia}}
[[Category:Gynaecological neoplasia]]